Castle Biosciences (NASDAQ: CSTL) is one of 29 public companies in the “Medical laboratories” industry, but how does it contrast to its peers? We will compare Castle Biosciences to related businesses based on the strength of its earnings, profitability, institutional ownership, risk, analyst recommendations, valuation and dividends.

Insider and Institutional Ownership

29.7% of Castle Biosciences shares are owned by institutional investors. Comparatively, 51.0% of shares of all “Medical laboratories” companies are owned by institutional investors. 14.2% of shares of all “Medical laboratories” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.


This table compares Castle Biosciences and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Castle Biosciences N/A N/A N/A
Castle Biosciences Competitors -124.53% -81.24% -29.48%

Analyst Ratings

This is a summary of current ratings and recommmendations for Castle Biosciences and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Castle Biosciences 0 0 4 0 3.00
Castle Biosciences Competitors 236 800 979 71 2.42

Castle Biosciences presently has a consensus target price of $40.00, suggesting a potential upside of 51.11%. As a group, “Medical laboratories” companies have a potential upside of 64.43%. Given Castle Biosciences’ peers higher probable upside, analysts clearly believe Castle Biosciences has less favorable growth aspects than its peers.

Valuation & Earnings

This table compares Castle Biosciences and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Castle Biosciences $51.87 million $5.28 million -32.68
Castle Biosciences Competitors $1.03 billion $53.91 million 29.99

Castle Biosciences’ peers have higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


Castle Biosciences peers beat Castle Biosciences on 7 of the 12 factors compared.

Castle Biosciences Company Profile

Castle Biosciences, Inc., a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; and two late-stage proprietary products in development, which address cutaneous squamous cell carcinoma and suspicious pigmented lesions, which are indications with high clinical need in dermatological cancer. It offers test services through physicians, physician assistants, and nurse practitioners. The company was founded in 2007 and is headquartered in Friendswood, Texas.

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with's FREE daily email newsletter.